This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

FIG. 1A

```
   1  agggagaggc agtgaccatg aaggctgtgc tgcttgccct gttgatggca
  51  ggcttggccc tgcagccagg cactgccctg ctgtgctact cctgcaaagc
 101  ccaggtgagc aacgaggact gcctgcaggt ggagaactgc acccagctgg
 151  gggagcagtg ctggaccgcg cgcatccgcg cagttggcct cctgaccgtc
 201  atcagcaaag gctgcagctt gaactgcgtg gatgactcac aggactacta
 251  cgtgggcaag aagaacatca cgtgctgtga caccgacttg tgcaacgcca
 301  gcggggccca tgccctgcag ccggctgccg ccatccttgc gctgctccct
 351  gcactcggcc tgctgctctg gggacccggc cagctatagg ctctgggggg
 401  ccccgctgca gcccacactg ggtgtggtgc cccaggcctt tgtgccactc
 451  ctcacagaac ctggcccagt gggagcctgt cctggttcct gaggcacatc
 501  ctaacgcaag tttgaccatg tatgtttgca ccccttttcc ccnaaccctg
 551  accttcccat gggccttttc caggattccn accnggcaga tcagttttag
 601  tganacanat ccgcntgcag atggcccctc caaccntttn tgttgntgtt
 651  tccatggccc agcattttcc acccttaacc ctgtgttcag gcacttnttc
 701  ccccaggaag ccttccctgc ccaccccatt tatgaattga gccaggtttg
 751  gtccgtggtg tcccccgcac ccagcagggg acaggcaatc aggagggccc
 801  agtaaaggct gagatgaagt ggactgagta gaactggagg acaagagttg
 851  acgtgagttc ctgggagttt ccagagatgg ggcctggagg cctggaggaa
 901  ggggccaggc ctcacatttg tgggntccc gaatggcagc ctgagcacag
 951  cgtaggccct taataaacac ctgttggata agccaaaaaa aaaaaaaa
```

FIG. 1B

MKAVLLALLMAGLALQPGTALLCYSCKAQVSNEDCLQV

ENCTQLGEQCWTARIRAVGLLTVISKGCSLNCVDDS

QDYYVGKKNITCCDTDLCNASGAHALQPAAAILALLPAL

GLLLWGPGQL

FIG. 2


ATGAAGACAGTTTTTTTTATCCTGCTGGCCACCTACTTAGCCCTGCATCCAGGTGCTGCT
1
60
TACTTCTGTCAAAAAAAATAGGACGACCGGTGGATGAATCGGGACGTAGGTCCACGACGA
M K T V F F I L L A T Y L A L H P G A A
CTGCAGTGCTATTCATGCACAGCACAGATGAACAACAGAGACTGTCTGAATGTACAGAAC
61
120
GACGTCACGATAAGTACGTGTCGTGTCTACTTGTTGTCTCTGACAGACTTACATGTCTTG
L Q C Y S C T A Q M N N R D C L N V Q N
TGCAGCCTGGACCAGCACAGTTGCTTTACATCGCGCATCCGGGCCATTGGACTCGTGACA
121
180
ACGTCGGACCTGGTCGTGTCAACGAAATGTAGCGCGTAGGCCCGGTAACCTGAGCACTGT
C S L D Q H S C F T S R I R A I G L V T
GTTATCAGTAAGGGCTGCAGCTCACAGTGTGAGGATGACTCGGAGAACTACTATTTGGGC
181
240
CAATAGTCATTCCCGACGTCGAGTGTCACACTCCTACTGAGCCTCTTGATGATAAACCCG
V I S K G C S S Q C E D D S E N Y Y L G
AAGAAGAACATCACGTGCTGCTACTCTGACCTGTGCAATGTCAACGGGGCCCACACCCTG
241
300
TTCTTCTTGTAGTGCACGACGATGAGACTGGACACGTTACAGTTGCCCCGGGTGTGGGAC
K K N I T C C Y S D L C N V N G A H T L
AAGCCACCCACCACCCTGGGGCTGCTGACCGTGCTCTGCAGCCTGTTGCTGTGGGGCTCC
301
360
TTCGGTGGGTGGTGGGACCCCGACGACTGGCACGAGACGTCGGACAACGACACCCCGAGG
K P P T T L G L L T V L C S L L L W G S
AGCCGTCTGTAGGCTCTGGGAGAGCCTACCATAGCCCGATTGTGAAGGGATGAGCTGCAC
361
420
TCGGCAGACATCCGAGACCCTCTCGGATGGTATCGGGCTAACACTTCCCTACTCGACGTG
S R L *
TCCACCCCACCCCCACACAGG
421
441
AGGTGGGGTGGGGGTGTGTCC

FIG. 3


1 MKIFLPVLLAALLLGVERASS hSCA-2
1 MKAVLLALLLMAGLALQPGTA hPSCA
1 MKTVLFLLLATYLALHPGAA mPSCA
21 LMCFSCLNQKSN*LYCLKPTI
21 LLCYSCKAQVSN*EDCLQVEN*
21 LQCYSCTAQMNN*RDCLNVQN*
41 CSDQDNYCVTVSASAGIGNL
41 CTQLGEQCWTARIRAVGLLT
41 CSLDQHSCFTSRIRAIGLVT
61 VTFGHSLSKTCSPACPIPEG
61 V-----ISKGCSLNCVDDSQ
61 V-----ISKGCSSQCEDDSE
81 VNVGVASMGISCCQSFLCN*F
76 DYYVGKK-N*ITCCDTDLCN*A
76 NYYLGKK-N*ITCCYSDLCN*V
101 SAADGGLRASVTLLGAGLLL
95 SGAHALQPAAAILALLPALG
95 NGAHTLKPPTTLGLLTVLCS
121 SLLPALLRFGP
115 LLLWGPGQL--
115 LLLWGSSRL--

FIG. 4



HYDROPHOBICITY PLOT OF PSCA


SIGNAL
SEQUENCE
GPI
SIGNAL
= glycosylation
SITE

FIG. 5

FIG. 6


PROSTATE
PROSTATE
PROSTATE
BLADDER
BLADDER
BLADDER CARCINOMA
KIDNEY
KIDNEY
TESTIS
S. INTESTINE
LAPC9


+CONTROL
TONSILS
THYMUS
SPLEEN
LEUKOCYTES
LYMPH NODE
FETAL LIVER
BONE MARROW
THYMUS
TESTIS
SPLEEN
SM. INTESTINE
PROSTATE
LEUKOCYTES
OVARY
COLON
SKELETAL MUSCLE
PLACENTA
PANCREAS
LUNG
LIVER
KIDNEY
HEART
BRAIN
PSCA

FIG. 7A


DU145
KCL22
COLO 205
A431
HELA
PC3
LAPC4 C.L.
LAPC9 AD
LAPC4 AI
LAPC4 AD
LAPC4 IT
PROSTATE
BRAIN
PSCA
β-ACTIN

FIG. 7B

FIG. 8A



FIG. 8B



FIG. 8C





FIG. 9A


~1kb
PANCREAS
KIDNEY
SKELETAL MUSCLE
LIVER
LUNG
PLACENTA
BRAIN
HEART
PERIPHERAL LEUKOCYTES
COLON
SMALL INTESTINE
OVARY
TESTIS
PROSTATE
THYMUS
SPLEEN
PSCA

FIG. 9B


72 HRS
KCL22
COLO 205
A431
HELA
DU145
PC3
LNCAP
LAPC4 C.L.
LAPC3 AI
LAPC9
LAPC4 IT
LAPC4 AI
LAPC4 AD
BPH
4 HRS
KCL22
COLO 205
A431
HELA
DU145
PC3
LNCAP
LAPC4 C.L.
LAPC3 AI
LAPC9
LAPC4 IT
LAPC4 AI
LAPC4 AD
BPH
PSCA

FIG. 10A


4 HRS
PSM
BPH
LAPC4 AD
LAPC4 AI
LAPC4 IT
LAPC9
LAPC3 AI
LAPC4 C.L.
LNCAP
PC3
DU145
HELA
A431
COLO 205
KCL22
72 HRS
BPH
LAPC4 AD
LAPC4 AI
LAPC4 IT
LAPC9
LAPC3 AI
LAPC4 C.L.
LNCAP
PC3
DU145
HELA
A431
COLO 205
KCL22

FIG. 10B


4 HRS
PSA
BPH
LAPC4 AD
LAPC4 AI
LAPC4 IT
LAPC9
LAPC3 AI
LAPC4 C.L.
LNCAP
PC3
DU145
HELA
A431
COLO 205
KCL22
72 HRS
BPH
LAPC4 AD
LAPC4 AI
LAPC4 IT
LAPC9
LAPC3 AI
LAPC4 C.L.
LNCAP
PC3
DU145
HELA
A431
COLO 205
KCL22
ETBR

FIG. 10C

FIG. 11A

FIG. 11B



FIG. 11C

FIG. 12A





FIG. 12B


293T971003008\FL2-H\FL2-Height
200
100
0
M1
10^0 10^1 10^2 10^3 10^4
293T CONTROL
293T971003010\FL2-H\FL2-Height
200
100
0
M1
10^0 10^1 10^2 10^3 10^4
293T + PSCA
293T971003012\FL2-H\FL2-Height
200
100
0
M1
10^0 10^1 10^2 10^3 10^4
LAPC-4

FIG. 12C

FIG. 13



FIG. 14A


LAPC9
CONTROL
mAB 3E6
mouse polyclonal
mAb 1G8
COUNTS
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
FL1-H

FIG. 14B


LAPC4
COUNTS
70
60
50
40
30
20
10
0
mAB 3E6
mAb 1G8
CONTROL
mouse polyclonal
10^0
10^1
10^2
10^3
10^4
FL1-H

FIG. 14C


PREC
CONTROL
mAb 1G8
mouse polyclonal
mAB 3E6
COUNTS
FL1-H
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4

EPITOPE MAP

mAb	ISOTYPE		FL (18-98)	N (2-50)	M (46-109)	C (85-123)
1G8	IgG1	k	2.039	0.007	0.628	0.000
2H9	IgG1	k	1.318	0.863	0.032	0.021
3C5	IgG2a	k	2.893	1.965	0.016	0.005
3E6	IgG3	k	0.328	0.024	0.069	0.370
4A10	IgG2a	k	2.039	1.315	0.000	0.014
2A2	IgG2a	k	1.366	0.733	0.010	0.003
3G3	IgG2a	k	2.805	1.731	0.004	0.000

FIG. 15A



FIG. 15B

FIG. 16A


PROSTATE STEM CELL ANTIGEN (PSCA) IS A GPI-ANCHORED PROTEIN
hSCA-2
hPSCA
mPSCA

PROSTATE STEM CELL ANTIGEN (PSCA) IS A GPI-ANCHORED PROTEIN



FIG. 16B

FIG. 17

FISH ANALYSIS OF PSCA AND c-myc IN PROSTATE CANCER

GAIN CHROMOSOME 8

AMPLIFICATION





#34 c-myc

#75 c-myc

#34 PSCA

#75 PSCA





FIG. 18





FIG. 19

FIG. 20



FIG. 21

PSCA IMMUNOSTAINING OF PRIMARY TUMORS



patient 1:mAb 1G8



patient 2:mAb 1G8

patient 3:mAb 1G8



patient 4:mAb 3E6

FIG. 22



FIG. 23

FIG. 24

FIG. 25



PSCA NORTHERN



FIG. 26



FIG. 27

PSCA IMMUNOSTAINING OF BONY METASTASES



Patient 5: H and E and mAb 1G8

Patient 4: H and E and mAb 3E6

FIG. 28



FIG. 29

FIG. 30





FIG. 31

FIG. 32



FIG. 33


PSCA EXPRESSION IN LAPC-9 XENOGRAFT BY FACS
SECONDARY ANTIBODY
1G8
2H9
4A10
3C5
3E6


anti-PSCA mAbs
1G8
2H9
3C5
3E6
4A10
48 kd
21.5 kd
12.5 kd
IMMUNOBLOT:
293T-PSCA

FIG. 34

FIG. 35

IMMUNOFLUORESCENT STAINING OF LNCaP-PSCA CELLS





FIG. 36


anti-PSCA mAbs
ISOTYPE CONTROL
1G8
2H9
3C5
3E6
4A10
215 kd
12.5 kd
IMMUNOPRECIPITATION:
293T-PSCA

FIG. 37


IMMUNOHISTOCHEMICAL STAINING OF NORMAL PROSTATE
NORMAL: ISOTYPE CONTROL
NORMAL: PSCA mAb 3E6
NORMAL: PSCA mAb 1G8
ATROPHY: PSCA mAB 2H9

FIG. 38

FIG. 39A





FIG. 39B

FIG. 40A





FIG. 40B

TRANSGENIC MOUSE MODELS OF PROSTATE CANCER

FIG. 41



TRANSGENE	TARGET TISSUES	CHARACTERISTICS
C3(1) (−3 kb)/ SV40 LARGE+SMALL, T MAROULAKOU et al. 1994 PNAS	PROSTATE (SECRETORY CELLS) URETHRAL, MAMMARY AND SWEAT GLAND	LOW-GRADE PIN 8-12 WKS HIGH-GRADE PIN 8-12 WKS INVASIVE CARCICINOMA 28 WKS NO METASTASES
PROBASIN (−426 bp)/ SV40 LARGE+SMALL, T GREENBERG et al. 1995 PNAS	PROSTATE (SECRETORY CELLS)	LOW-GRADE PIN 5-8 WKS HIGH-GRADE PIN 8-12 WKS INVASIVE CARCICINOMA 12 WKS METASTASES IN LYMPH NODE, LUNG, LIVER AND BONE
CRYPTDIN2 (−6.5 kb)/ SV40 LARGE+SMALL, T GARABEDIAN et al. 1998 PNAS	PROSTATE (NEUROENDOCRINE CELLS) SMALL INTESTINE	LOW-GRADE PIN 8-12 WKS HIGH-GRADE PIN 8-12 WKS INVASIVE CARCICINOMA 16 WKS METASTASES IN LYMPH NODE, LUNG, LIVER, AND BONE


REPORTER GENE CONSTRUCTS FOR TRANSFECTION ASSAY
NotI
-9 kb
HindIII
-7 kb
BglII
-6 kb
BamHI
-3 kb
KpnI
-1 kb
TATA
PSCA GENE
CODING EXON
NONCODING
EXON
PSCA PROMOTER
LUCIFERASE
pGL3-PSCA (9 kb)
LUCIFERASE
pGL3-PSCA (6 kb)
LUCIFERASE
pGL3-PSCA (3 kb)
LUCIFERASE
pGL3-PSCA (1 kb)
LUCIFERASE
pGL3-BASIC
LUCIFERASE
pGL3-CMV
CMV PROMOTER

FIG. 42


RELATIVE LUCIFERASE ACTIVITY TO CMV-LUC
0
5
10
15(%)
PrEC (PROSTATE)
LNCaP(PROSTATE)
LAPC4 (PROSTATE)
HT1376 (BLADDER)
293T (KIDNEY)

FIG. 43


IDENTIFICATION OF PROSTATE-SPECIFIC ELEMENTS
WITHIN PSCA PROMOTER SEQUENCES
PrEC CELLS
(ANDROGEN-INDEPENDENT
PROSTATE BASAL CELLS)
LNCaP CELLS
(ANDROGEN-DEPENDENT
PROSTATE SECRETORY CELLS)
PSCA PROMOTER
0 kb
1 kb
3 kb
6 kb
9 kb
LUC
0
5
10
RELATIVE LUCIFERASE ACTIVITY
TO CMV-LUC (%)

FIG. 44

FIG. 45

UPDATE OF TRANSGENIC MOUSE PROJECTS



NUMBER OF FOUNDERS (DNA POSITIVE)
2
1
6
8
3
9


WHOLE-MOUNT GREEN FLUORECENCE IMAGE
TRANSGENIC
NON-TRANSGENIC
NEGATIVE TISSUES
STOMACH
SMALL INTESTINE
COLON
SEMINAL VESICLE
URETHRA
TESTIS
LIVER
KIDNEY
LUNG
BRAIN
HEART
SKELETAL MUSCLE
OVARY
UTERUS
PROSTATE (A25-106-2)
BLADDER (A25-104)
SKIN (A25-106-2)

FIG. 46


HUMAN
SPLEEN
THYMUS
PROSTATE
TESTIS
OVARY
S. INT.
COLON
PBL
HEART
BRAIN
PLACENTA
LUNG
LIVER
MUSCLE
KIDNEY
PANC.
hPSCA
NORTHERN ANALYSIS
MOUSE
ANT. PROSTATE
DORSO/LAT. PROSTATE
VENTRAL PROSTATE
BLADDER
SEMINAL VESICLE
URETHRA
TESTIS
KIDNEY
ESOPHAGUS
CARDIAC STOMACH
BODY OF STOMACH
PYLORIC STOMACH
DUODENUM
SMALL INTESTINE
COLON
SALIVARY GLAND
SPLEEN
THYMUS
BONE MARROW
SKELETAL MUSCLE
HEART
BRAIN
EYE
LUNG
LIVER
SKIN
mPSCA
mG3PDH
RT-PCR

FIG. 47

FIG. 48


Mouse IgG Control
Tumor volume (mm3)
1000
750
500
250
0
32
35
39
42
47
54
61
Days
1
2
3
4
5
6
7
8
9
10


Anti-PSCA
Tumor volume (mm3)
1000
750
500
250
0
32
35
39
42
47
54
61
Days
11
12
13
14
15
16
17
18
19
20

FIG. 49

A

mAb	Isotype	Epitope recognized (OD 450 nm) F (18-98)	N (2-50)	M (46-109)	C (85-123)
1G8	IgG1 k	1.485	0.004	1.273	0.003
2A2	IgG2a k	0.973	0.631	0.023	0.010
2H9	IgG1 k	1.069	1.026	0.002	0.001
3C5	IgG2a k	1.916	1.709	0.006	0.002
3E6	IgG3 k	1.609	0.036	1.133	2.118
3G3	IgG2a k	2.805	1.731	0.004	0.000
4A10	IgG2a k	1.053	0.493	0.000	0.001

B



FIG. 50

A



B



Anti-IgG2a HRP

Anti-PSCA mAbs 3C5+4A10+2A2 (IgG2a)

PSCA

Affinity purified anti-peptide polyclonal
+ mAb 1G8 (IgG1)

FIG. 51

A



B

Sample	OD+range (n=2)	ng/ml
vector	0.005+0.001	ND
vector+hu serum	0.004+0.001	ND
secPSCA	2.695+0.031	32.92
secPSCA+hu serum	2.187+0.029	26.55

FIG. 52


LNCaP/LNCaP-PSCA/293T Cell Pellet
Negative Control
LAPC9 AD Xenograft
Negative Control
BPH
Negative Control
Prostate Carcinoma
Negative Control

FIG. 53


Mouse IgG
Tumor volume (mm3)
1800
1350
900
450
0
22
26
29
33
36
41
46
Days
1
2
3
4
5
6
7
8
9
10


Anti-PSCA
Tumor volume (mm3)
1800
1350
900
450
0
22
26
29
33
36
41
46
Days
11
12
13
14
15
16
17
18
19
20


Bovine IgG
Tumor volume (mm3)
1800
1350
900
450
0
22
26
29
33
36
41
Days
21
22
23
24
25

FIG. 54


Mouse IgG
Tumor volume (mm3)
1400
1050
700
350
0
19
22
26
29
34
39
42
Days
1
2
3
4
5
6


1G8 mAb
Tumor volume (mm3)
1400
1050
700
350
0
19
22
26
29
34
39
42
Days
7
8
9
10
11
12
13

FIG. 55


800
600
400
200
0
Tumor volume (mm3)
21
25
28
32
35
39
42
Days
Mouse IgG
2A2


800
600
400
200
0
Tumor volume (mm3)
21
25
28
32
35
39
42
Days
Mouse IgG
2H9

FIG. 56


50
40
30
20
10
0
PSA Level (ng/ml)
3
4
5
6
Weeks
Mouse IgG
2A2


50
40
30
20
10
0
PSA Level (ng/ml)
3
4
5
6
Weeks
Mouse IgG
2H9

FIG. 57


2400
1800
1200
600
0
Tumor volume (mm3)
11
14
18
21
25
28
Days
MIgG
3C5

FIG. 58

```
TGCTTCTTCCTGATGGCAGTGGTTATAGGAGTCAATTCAGAGGTTCAGCTGCAGCAGTCT  60
 C  F  F  L  M  A  V  V  I  G  V  N  S  E  V  Q  L  Q  Q  S   20

                                                    ┌─────
GGGGCAGAACTTGTGAGGTCAGGGGCCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTC 120
 G  A  E  L  V  R  S  G  A  S  V  K  L  S  C  T  A  S  G  F   40

 ──────── CDR1 ──────┐
AACATTAAAGACTACTATATACACTGGGTGAATCAGAGGCCTGACCAGGGCCTGGAGTGG 180
 N  I  K  D  Y  Y  I  H  W  V  N  Q  R  P  D  Q  G  L  E  W   60

          ┌──────────────────────── CDR2 ──────────────────────┐
ATTGGATGGATTGATCCTGAGAATGGTGACACTGAATTTGTCCCGAAGTTCCAGGGCAAG 240
 I  G  W  I  D  P  E  N  G  D  T  E  F  V  P  K  F  Q  G  K   80

GCCACTATGACTGCAGACATTTTCTCCAACACAGCCTACCTGCACCTCAGCAGCCTGACA 300
 A  T  M  T  A  D  I  F  S  N  T  A  Y  L  H  L  S  S  L  T  100

                                    ┌ CDR3 ┐
TCTGAAGACACTGCCGTCTATTACTGTAAAACGGGGGGTTTCTGGGGCCAAGGGACTCTG 360
 S  E  D  T  A  V  Y  Y  C  K  T  G  G  F  W  G  Q  G  T  L  120

GTCACTGTCTCTGCAGCCAAAACGACACCCCCATCTGTCTATCCACTG
 V  T  V  S  A  A  K  T  T  P  P  S  V  Y  P  L
```

FIG. 59


TTGGTAGCAACAGCCTCAGATGTCCACTCCCAGGTCCAACTGCAGCAACCTGGGTCTGAA 60
L V A T A S D V H S Q V Q L Q Q P G S E 20
CTGGTGAGGCCTGGAACTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTATACATTCTCC 120
L V R P G T S V K L S C K A S G Y T F S 40
CDR1
AGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAAAT 180
S Y W M H W V K Q R P G Q G L E W I G N 60
ATTGACCCTGGTAGTGGTTACACTAACTACGCTGAGAACCTCAAGACCAAGGCCACACTG 240
I D P G S G Y T N Y A E N L K T K A T L 80
CDR2
ACTGTAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGAC 300
T V D T S S S T A Y M Q L S S L T S E D 100
TCTGCAGTCTATTACTGTACAAGCCGATCTACTATGATTACGACGGGATTTGCTTACTGG 360
S A V Y Y C T S R S T M I T T G F A Y W 120
CDR3
GGCCAAGGGACTCTGGTCACTGTCTCTGCAGCTACAACAACAGCCCCATCTGTCTATCCA 420
G Q G T L V T V S A A T T T A P S V Y P 160
CTGGCC
L A

FIG. 60

```
AATGACTTCGGGTTGAGCTGGGTTTTTATTATTGTTCTTTTAAAAGGGGTCCGGAGTGAA  60
 N  D  F  G  L  S  W  V  F  I  I  V  L  L  K  G  V  R  S  E   20

GTGAGGCTTGAGGAGTCTGGAGGAGGCTGGGTGCAACCTGGAGGATCCATGAAACTCTCC 120
 V  R  L  E  E  S  G  G  G  W  V  Q  P  G  G  S  M  K  L  S   40

TGTGTAGCCTCTGGATTTACTTTCAGTAATTACTGGATGACTTGGGTCCGCCAGTCTCCA 180
 C  V  A  S  G  F  T  F  S  N  Y  W  M  T  W  V  R  Q  S  P   60
                  CDR1

GAGAAGGGGCTTGAGTGGGTTGCTGAAATTCGATTGAGATCTGAAAATTATGCAACACAT 240
 E  K  G  L  E  W  V  A  E  I  R  L  R  S  E  N  Y  A  T  H   80
                                                CDR2

TATGCGGAGTCTGTGAAAGGGAAATTCACCATCTCAAGAGATGATTCCAGAAGTCGTCTC 300
 Y  A  E  S  V  K  G  K  F  T  I  S  R  D  D  S  R  S  R  L  100

TACCTGCAAATGAACAACTTAAGACCTGAAGACAGTGGAATTTATTACTGTACAGATGGT 360
 Y  L  Q  M  N  N  L  R  P  E  D  S  G  I  Y  Y  C  T  D  G  120

CTGGGACGACCTAACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGACA 420
 L  G  R  P  N  W  G  Q  G  T  L  V  T  V  S  A  A  K  T  T  140
    CDR3

CCCCCATCTGTCTATCCACTGGCCCCTTGTGTA
 P  P  S  V  Y  P  L  A  P  C  V
```

FIG. 61

CDR1 Comparisons

1G8	$1gG_{1k}$	Middle	G	F	N	I	K	D	Y	Y	I	H
2H9	$1gG_{1k}$	N-Term.	G	F	T	F	S	N	Y	W	M	T
4A10	$1gG_{2ak}$	N-Term.	G	Y	T	F	S	S	Y	W	M	H

CDR2 Comparisons

1G8	$1gG_{1k}$	W	I	D	P	E	N	G	D	T	E	F	V	P	K	F	Q	G
2H9	$1gG_{1k}$	E	I	R	L	R	S	E	N	Y	A	T	H	Y	A	E	S	V	K	G
4A10	$1gG_{2ak}$	N	I	D	P	G	S	G	Y	T	N			Y	A	E	N	L	K	T

CDR3 Comparisons

1G8	$1gG_{1k}$	G	G	F								
2H9	$1gG_{1k}$	L	G	R	P	N						
4A10	$1gG_{2ak}$	R	S	T	M	I	T	T	G	F	A	Y

FIG. 62



FIG. 63



1. Prostate
2. LAPC-4 AD
3. LAPC-4 AI
4. LAPC-9 AD
5. LAPC-9 AI
6. PANC-1
7. BxPC-3
8. HPAC
9. Capan-1

FIG. 64



1. LAPC-4 AD
2. LAPC-9 AI
3. LNCaP
4. LNCaP-PSCA

5. HPAC
6. Capan-1
7. ASPC-1

FIG. 65


LAPC-9
Tumor volume (mm 3)
1200
900
600
300
0
19
22
26
29
34
39
42
Days
Mouse IgG
1G8


PC-3
Tumor volume (mm 3)
300
200
100
0
25
29
33
39
Days
Mouse IgG
1G8

FIG. 66

A)



	9	15	22	30	37	44	51
PBS	2.3	20	119	386	583		
1G8	2.8	8.3	16.2	71	198	234	351

Days

Mean PSA Levels (ng/ml)

B)



	13	21	27	34
PBS	78	412	422	418
1G8	64	268	294	315

Days

Mean PSA Levels (ng/ml)

FIG. 67

A)


100
80
60
40
20
0
% Survival
0
15
30
45
60
75
90
105
Days
PBS
1G8

B)


100
80
60
40
20
0
% Survival
0
20
40
60
80
100
120
Days
PBS
1G8

FIG. 68

A)



	9	16	22	29	36
PBS	23	126	322	519	555
3C5	3	21	95	290	428

Mean PSA Levels (ng/ml)

B)



	7	14	21	28
PBS	14	107	329	449
3C5	16	63	229	351

Mean PSA Levels (ng/ml)

FIG. 69

A)


100
80
60
40
20
0
% Survival
0
25
50
75
100
125
Days
PBS
3C5

B)


100
80
60
40
20
0
% Survival
0
10
20
30
40
50
60
70
80
90
Days
PBS
3C5

FIG. 70



	9	15	23	29	36	43
PBS	149	343	385	458	533	601
Dox	148	250	337	371	473	577
1G8	135	208	235	276	408	479
1G8 + Dox	129	205	242	260	359	387

Days

FIG. 71

PSCA 3C5 MAb Localizes within LAPC9AD Xenograft Tissue

3C5 Treated



mIgG Treated



3C5 Anti-PSCA MAb is Localized to Established LAPC-9 Tumors



Western blot developed with α-mIgG/κ

FIG. 72

SPECIFIC TARGETING OF THE 1G8 ANTI-PSCA MAb TO ESTABLISHED LAPC-9 TUMORS



Method: Mice bearing established LAPC-9 tumors (>100 mm^3) were injected with either mIgG or the anti-PSCA MAb 1G8. Tumors were harvested a week later and made into protein lysates for Western analysis

FIG. 73